DIAP2 functions as a mechanism-based regulator of drICE that contributes to the caspase activity threshold in living cells by Ribeiro, Paulo S. et al.
T
H
E
J
O
U
R
N
A
L
O
F
C
E
L
L
B
I
O
L
O
G
Y
JCB: ARTICLE
© The Rockefeller University Press    $30.00
The Journal of Cell Biology, Vol. 179, No. 7, December 31, 2007 1467–1480
http://www.jcb.org/cgi/doi/10.1083/jcb.200706027
JCB 1467
Introduction
Caspases are best known for their role in executing apoptosis, 
however, they also play important signaling roles in nonapoptotic 
processes, such as regulation of actin dynamics, innate immu-
nity, and cell proliferation, differentiation, and survival (Lamkanfi   
et al., 2007). Under such conditions, caspases are activated without 
killing the cell.
Given the irreversible nature of caspase-mediated proteol-
ysis, caspases’ activation and activity is subject to complex regula-
tion. After zymogen activation, caspase activity can be controlled 
by various cellular and viral inhibitors. Interestingly, the viral 
inhibitors CrmA and p35 neutralize caspases through a funda-
mentally different mechanism than cellular inhibitors such as 
the inhibitor of apoptosis (IAP) proteins (Salvesen and Duckett, 
2002). CrmA and p35 function as “suicide substrates,” whereby 
cleavage of CrmA and p35 is required to block the caspase. 
Initially, CrmA and p35 are cleaved through a mechanism that 
  resembles substrate hydrolysis. However, during the reaction, 
the protease’s catalytic machinery is trapped via covalent link-
age (Stennicke and Salvesen, 2006). This strategy is referred to 
as “mechanism-based” inhibition because it relies on the cas-
pase’s catalytic property. So far, cellular-derived mechanism-
based caspase inhibitors have not been identifi  ed.
IAPs are defi  ned by the presence of one to three copies of 
the baculovirus IAP repeat (BIR) domain, which functions as a 
protein interaction module. In addition, certain but not all IAPs 
also carry a C-terminal RING fi  nger domain, which provides 
these molecules with E3 ubiquitin–protein ligase activity. 
In Drosophila melanogaster, DIAP1-mediated inhibition of cas-
pases is indispensable for cell survival. Mutations that abrogate 
the physical association of DIAP1 with the effector caspases 
drICE or DCP-1 or the initiator caspase Dronc cause spontane-
ous caspase activation and cell death (Wang et al., 1999; Goyal 
et al., 2000; Lisi et al., 2000; Rodriguez et al., 2002; Zachariou 
et al., 2003).
The involvement of the second D. melanogaster IAP 
(DIAP2) in regulating caspases is less clear. Overexpression stud-
ies suggest that DIAP2 can suppress cell death induced by the IAP 
antagonists reaper (Rpr) and head involution defective (Hid; 
Hay et al., 1995) and suppress apoptosis induced by diap1-RNAi 
DIAP2 functions as a mechanism-based regulator 
of drICE that contributes to the caspase activity 
threshold in living cells
Paulo S. Ribeiro,
1,2 Erina Kuranaga,
3 Tencho Tenev,
1 François Leulier,
1,4 Masayuki Miura,
3 and Pascal Meier
1
1Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, England, UK
2Programa Gulbenkian de Doutoramento em Biomedicina, Instituto Gulbenkian de Ciência, Oeiras 2781-901, Portugal
3Department of Genetics, Graduate School of Pharmaceutical Sciences, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
4Centre National de la Recherche Scientiﬁ  que, Centre de Génétique Moléculaire, Gif-sur-Yvette 91190, France
  I
n addition to their well-known function in apoptosis, 
caspases are also important in several nonapoptotic 
processes. How caspase activity is restrained and shut 
down under such nonapoptotic conditions remains un-
known. Here, we show that Drosophila melanogaster in-
hibitor of apoptosis protein 2 (DIAP2) controls the level of 
caspase activity in living cells. Animals that lack DIAP2 have 
higher levels of drICE activity. Although diap2-deﬁ  cient 
cells remain viable, they are sensitized to apoptosis fol-
lowing treatment with sublethal doses of x-ray irradiation. 
We ﬁ nd that DIAP2 regulates the effector caspase drICE 
through a mechanism that resembles the one of the cas-
pase inhibitor p35. As for p35, cleavage of DIAP2 is re-
quired for caspase inhibition. Our data suggest that 
DIAP2 forms a covalent adduct with the catalytic machin-
ery of drICE. In addition, DIAP2 also requires a functional 
RING ﬁ  nger domain to block cell death and target drICE 
for ubiquitylation. Because DIAP2 efﬁ  ciently interacts with 
drICE, our data suggest that DIAP2 controls drICE in its 
apoptotic and nonapoptotic roles.
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(Leulier et al., 2006b). Because diap1-RNAi– mediated  death 
is independent of IAP antagonists, this suggests that DIAP2 
can neutralize caspases. Of the seven D. melanogaster caspases, 
DIAP2 only binds to the effector caspase drICE and the atypical 
caspase Strica (Doumanis et al., 2001). In contrast, DIAP1 ex-
hibits much broader caspase selectivity because it inhibits Dronc, 
drICE, and DCP-1.
Based on the domain architecture and sequence align-
ments, DIAP2 is the closest homologue to mammalian IAPs. 
In contrast, DIAP1 is more related to IAPs from insect viruses. 
Like the mammalian x-linked IAP (XIAP), DIAP2 carries three 
BIR domains and a C-terminal RING fi  nger. XIAP blocks apop-
tosis by acting as a potent enzymatic inhibitor of caspase-3, -7, 
and -9 (Shi, 2002). Residues located immediately upstream of 
XIAP’s BIR2 domain directly bind to the active site pockets of 
caspase-3 and -7, thereby obstructing substrate entry (Chai et al., 
2001; Huang et al., 2001; Riedl et al., 2001a; Silke et al., 2001; 
Suzuki et al., 2001). Importantly, XIAP is not cleaved by cas-
pases because it binds to the catalytic pockets of effector cas-
pases in a reverse orientation. Thus, XIAP relies on allosteric 
mechanisms to block effector caspase activity. XIAP’s ability to 
suppress effector caspases depends on the side chain of Asp148 
and, to a lesser extent, Val146. It is predicted that Asp148 must 
be conserved in all IAPs that neutralize effector caspases. Con-
sistently, Asp148 is conserved in cIAP1 and 2. Intriguingly, 
DIAP2 also shows homology to XIAP’s Val146 and Asp148, as 
it carries equivalent residues at Val98 and Asp100 (Silke et al., 
2001). In contrast, these residues are absent in DIAP1.
Of all the IAPs, XIAP appears to be the only IAP that po-
tently inhibits caspases in vitro (Eckelman et al., 2006). Other 
IAPs, such as cIAP1 and 2, are poor inhibitors of caspases under 
these conditions. cIAP1 and 2 may rely on their E3 ligase activ-
ity to block caspases in vivo, making them caspase regulators 
rather than inhibitors. Although DIAP1 is a relatively good 
 inhibitor  of  D. melanogaster caspases in vitro (Yan et al., 2004), 
DIAP1–caspase physical association alone is insuffi  cient to neu-
tralize caspases in the fl  y. In addition to binding, DIAP1 uses two 
independent mechanisms to regulate caspases. One relies on the 
E3 ubiquitin protein ligase activity of DIAP1’s own RING fi  n-
ger, whereas the other, the “N-end” rule, functions independently 
of this domain. The RING fi  nger of DIAP1 is required to target 
the proform of the initiator caspase Dronc for ubiquitylation and 
inactivation (Wilson et al., 2002). In contrast, active effector cas-
pases seem to be neutralized through a mechanism that involves 
both the RING fi  nger domain as well as the N-end rule degrada-
tion machinery that is recruited by DIAP1 (Ditzel et al., 2003).
In D. melanogaster, developmentally regulated apoptosis 
is induced by the IAP antagonists Rpr, Grim, and Hid (Salvesen 
and Abrams, 2004). Embryos lacking rpr, grim, and hid are vir-
tually devoid of apoptosis and die at the end of embryogenesis 
with accumulation of supernumeral cells (White et al., 1994). 
The current model suggests that Rpr, Grim, and Hid induce apop-
tosis by binding to the BIR domains of DIAP1, thereby liberat-
ing caspases from IAP inhibition. Furthermore, IAP antagonists 
also deplete DIAP1 protein levels by promoting its degradation 
(Ryoo et al., 2002; Yoo et al., 2002) and cause mitochondrial 
permeability (Abdelwahid et al., 2007). Although Rpr, Grim, and 
Hid effi  ciently antagonize DIAP1, they also associate with DIAP2 
(Vucic et al., 1997, 1998; Leulier et al., 2006b). This implies 
that DIAP2 contributes to the overall antiapoptotic threshold of 
a cell, a view that is supported by the notion that RNAi-mediated 
knockdown of DIAP2 sensitizes cultured cells to stress-induced 
death (Zimmermann et al., 2002). However, analyses using diap2 
mutant fl  ies have failed to expose any involvement of DIAP2 in 
regulating programmed cell death. Instead, they have shown 
that DIAP2 is required for nuclear factor κB activation during 
the innate immune response in D. melanogaster (Gesellchen et al., 
2005; Kleino et al., 2005; Leulier et al., 2006a; Huh et al., 2007).
Here, we have used the fl  uorescence resonance energy 
transfer (FRET)–based caspase-3 indicator SCAT3 to examine 
DIAP2’s role in regulating caspase activity in vivo. Using diap2 
mutant animals, we found that these animals harbor signifi  cantly 
increased levels of drICE activity. Consistent with higher levels 
of active caspases, diap2 mutant cells are sensitized to apoptosis 
after exposure to sublethal doses of x-ray irradiation. Further-
more, we fi  nd that DIAP2 tightly associates with the effector 
caspase drICE and that DIAP2-mediated drICE inhibition re-
quires DIAP2 cleavage at Asp100. Our data are consistent with 
the notion that after cleavage, the caspase forms a covalent adduct 
with DIAP2, which results in the stabilization of the DIAP2–
caspase complex. This mode of caspase binding is similar to that 
of p35 or CrmA. However, in addition to the mechanism-based 
trapping, DIAP2 also requires a functional RING fi  nger domain 
to neutralize drICE-mediated cell death. Consistently, we fi  nd 
that DIAP2 robustly ubiquitylates drICE in vivo.
Results
Loss of DIAP2 results in deregulated 
drICE activity in vivo
To investigate the role of endogenous DIAP2 in regulating 
drICE in vivo, we examined whether diap2 mutant animals dis-
play higher basal levels of caspase activity. In vivo caspase 
activity was measured using SCAT3, a FRET-based probe that 
detects active caspases (Fig. 1, A–H). In this system, caspase 
activation causes a decrease in the FRET signal, which results 
in a decrease of Venus/ECFP emission ratio (Takemoto et al., 
2003). Hedgehog-GAL4–driven expression of the UAS-SCAT3 
probe, which drives expression of the SCAT3 sensor in the pos-
terior part of the wing disc (Fig. 1, A–D and G), revealed that 
caspase activity is low in wing imaginal discs of wild-type (WT) 
third instar larvae. In contrast, FRET analysis of diap2 loss-
of-function mutants (diap2
7c; Leulier et al., 2006b) showed that 
caspase activity was signifi  cantly increased, as seen by the re-
duction of the FRET signal. Importantly, this increase in cas-
pase activity was completely suppressed in the presence of a 
diap2 genomic rescue transgene (Fig. 1, D, P[diap2
+]), which 
demonstrates that it is caused by the loss of diap2. Moreover, 
RNAi-mediated knockdown of drICE abolished the observed 
increase in caspase activity (Fig. 1 C). Together, these data sug-
gest that loss of diap2 results in an increase of drICE activity in 
wing discs. Similarly, salivary glands of diap2 mutant animals 
also displayed higher levels of endogenous caspase activity 
when compared with controls (Fig. 1, E, F, and H). Of note, the DIAP2-MEDIATED REGULATION OF DRICE • RIBEIRO ET AL. 1469
SCAT3 ratio of dying cells is around 1 (Fig. 1, A–F, blue; Take-
moto et al., 2007). Therefore, the observed ratio in diap2
7c 
mutant flies is nonapoptotic. Consistent with the FRET data, 
we also detected increased DEVDase activity (Ac-DEVD-MCA) 
in adult diap2 mutant animals (Fig. 1 I). Collectively, these re-
sults indicate that the loss of diap2 leads to increased basal lev-
els of drICE activity, albeit without causing cell death.
We next tested whether loss of DIAP2 sensitizes cells to 
sublethal doses of x-ray irradiation. To this end, we exposed 
third instar larvae to sublethal doses (1.5 Gy) of x-ray irradia-
tion and monitored cell death after 4 h using acridine orange 
(AO). In nonirradiated fl  ies, the number of AO-positive cells 
was low and comparable across all tested genotypes. However, 
after irradiation with 1.5 Gy, diap2
7c hemi- and homozygous 
Figure 1.  diap2 mutant cells have increased levels of active drICE. (A–H) Spectral analysis of WT and diap2 mutant wing discs (A–D and G) and salivary 
glands (E, F, and H). FRET ratio images are shown. Genotypes used: +;hh-GAL4/UAS-SCAT3 (A), diap2
7c;hh-GAL4/UAS-SCAT3 (B), diap2
7c/diap2
7c,UAS-
drICE-IR;hh-GAL4/UAS-SCAT3 (C), diap2
7c;hh-GAL4,UAS-SCAT3/P[diap2
+](D),  +;da-GAL4/UAS-SCAT3 (E), and diap2
7c;da-GAL4/UAS-SCAT3 (F). 
Changes in the emission ratio (530:475 nm, Venus/ECFP) of SCAT3 in the posterior region of wing discs (G) or salivary glands (H). The data shown repre-
sent an average of the FRET ratio in each tissue from >10 ﬂ  ies (mean ± SD). (I) Increased DEVDase activity in lysates from adult diap2 mutant animals. 
Caspase activity (mean ± SD) was determined using the ﬂ  uorescent substrate DEVD-MCA. (J–Q) DIAP2 mutant cells are sensitized to undergo cell death, as 
assessed by AO staining. Genotypes used: yw
1118 (J and N), diap2
7c/Def(2R)exel7138 (K and O), diap2
7c (L and P), and diap2
7c;P[diap2
+] (M and Q). 
(R) Quantiﬁ  cation of the number of AO-positive cells (mean ± SD). Bars, 100 μm.JCB • VOLUME 179 • NUMBER 7 • 2007  1470
fl  ies displayed a marked increase in AO-positive cells when com-
pared with WT fl  ies, which displayed no signifi  cant increase in 
AO-positive cells (Fig. 1, J–R). Importantly, this enhanced sen-
sitivity of diap2
7c mutants was rescued by a genomic construct 
of DIAP2. This indicates that loss of DIAP2 is responsible for 
the observed increase in cell death after irradiation and is con-
sistent with a model whereby DIAP2 contributes to the apoptotic 
threshold (see Fig. 8 A).
Binding of DIAP2 to drICE
We have previously shown that DIAP2 interacts with drICE 
(Leulier et al., 2006b). To identify the mode of caspase inhibi-
tion by DIAP2, we fi  rst established the mechanism through 
which DIAP2 binds to drICE. Because drICE activation results 
in the exposure of an evolutionarily conserved IAP-binding 
  motif (IBM) at the neo N terminus of its p20 subunit (Tenev et al., 
2005), we examined the role of this IBM for DIAP2 binding. 
Tandem affi  nity purifi  cation (TAP)–tagged DIAP2 was expressed 
in 293T cells (mammalian cells were chosen to avoid potential 
interference by DIAP1), purifi  ed (Rigaut et al., 1999), and subse-
quently incubated with extracts of cells expressing either drICE
WT 
or drICE
A29V lacking the Ala of the IBM (Fig. 2 B). The pro-
cessed and active form of drICE
WT was readily copurifi  ed by 
DIAP2 (Fig. 2 B). In contrast, DIAP2 failed to purify drICE
A29V 
from cellular extracts. Note, substitution of Ala29 to Val does 
not affect processing or activity of drICE (Fig. 2 B, compare 
lanes 1 and 2; Tenev et al., 2005), which indicates that the ob-
served differences in DIAP2 binding are caused by the lack of a 
functional IBM in drICE
A29V.
The Ala1 of IBMs anchors IBM-containing proteins to 
particular BIR domains (Wu et al., 2000, 2001). Therefore, we 
used DIAP2 point and truncation mutants to identify the BIR 
domain that is required for drICE binding (Fig. 2, C and D; and 
Fig. S1, available at http://www.jcb.org/cgi/content/full/jcb
.200706027/DC1). The BIR3 domain of DIAP2 was indispensable 
for drICE binding because mutation of this domain abolished 
drICE association (Fig. 2, C and D). In contrast, deletion of the 
BIR1 or RING fi  nger (Fig. S1 A) or disruption of the BIR2 through 
mutation of Cys149 to Gly or Asp163 to Ala did not abrogate 
the interaction with drICE. Although the BIR3 domain is neces-
sary for drICE binding, it is not suffi  cient, as the BIR3 domain 
in isolation failed to associate with drICE (Fig. S1 B).
Endogenous DIAP2 is processed by a p35-
sensitive caspase
We noticed that DIAP2 was readily cleaved by drICE (Fig. 2 B). 
To study whether DIAP2 cleavage also occurred in intact cells, 
we examined endogenous DIAP2 in normal D. melanogaster 
S2 cells. In agreement with N-terminal cleavage, we detected 
two distinct endogenous DIAP2 proteins with different mobil-
ities: full-length DIAP2 and a slightly faster migrating form 
refl  ecting a smaller DIAP2 protein (Fig. 3 B). RNAi-mediated 
depletion of DIAP2 showed that both forms were DIAP2 de-
rived. The presence of the smaller form was caspase dependent 
because it was signifi  cantly reduced in cells treated with the 
caspase inhibitor z-VAD-fmk or that expressed p35 (Fig. 3 B). 
Cleavage of DIAP2 is likely to be mediated by drICE, as drICE 
can directly cleave DIAP2 in vitro and RNAi-mediated deple-
tion of drICE reduces cleavage of endogenous DIAP2 in S2 
cells (Fig. 3 C and not depicted). DIAP2 carries two putative 
caspase cleavage sites at positions 92 and 100, N-terminal to 
the BIR2 domain (Fig. 3 A). Mutation of Asp100 to Glu, like 
Figure 2.  DIAP2 interacts with drICE in a BIR3- and IBM-dependent manner. (A) Schematic representation of DIAP2 proteins used in this paper. (B) The 
IBM mutant drICE
A29V fails to associate with DIAP2. Expression of drICE and drICE
A29V and their copuriﬁ  cation with DIAP2 was determined by immuno-
blot analysis using the indicated antibodies. TAP-puriﬁ  ed DIAP2 was detected by immunoblotting with an antibody recognizing the protein A portion 
of the TAP tag (designated as anti-TAP). (C and D) The DIAP2–drICE interaction requires the BIR3 domain, as mutation of this region abrogates 
drICE binding.DIAP2-MEDIATED REGULATION OF DRICE • RIBEIRO ET AL. 1471
z-VAD-fmk treatment, abrogated DIAP2 cleavage (Fig. 3 D). 
Under the same conditions, cleavage of WT DIAP2 and DIAP2
D92E 
(unpublished data) was not affected. This indicates that Asp100, 
which is evolutionarily conserved, is required for caspase-
 mediated  cleavage.
Next, we examined the cleavage status of endogenous 
DIAP2 under apoptotic conditions. Exposure to UV light or ex-
pression of Rpr triggered DIAP2 cleavage (Fig. 3 E and not de-
picted). Under the same conditions, DIAP1 was also cleaved 
(Fig. 3 E; Ditzel et al., 2003). Although a small proportion of 
DIAP1 and 2 was processed in untreated controls, exposure to 
UV light converted almost all full-length DIAP1 and 2 into their 
cleaved forms. DIAP2 cleavage occurred predominantly 2–3 h 
after UV exposure and at a time point where no apoptotic mor-
phological changes, signifi  cant drICE activation, or cleavage of 
Bicaudal, a bona fi  de caspase substrate (Martin, S., personal 
communication), was apparent (unpublished data). This sug-
gests that DIAP2 cleavage, like that of DIAP1 (Ditzel et al., 
2003), occurs early during apoptosis. Exposure to z-VAD-fmk 
restored the appearance of full-length DIAP1 and 2 (unpub-
lished data). Consistent with previous studies, DIAP1 protein 
levels rapidly diminished after UV treatment (Fig. 3 E; Muro et al., 
2005). Although DIAP2 was cleaved, DIAP2 levels were not 
depleted to the same extent as DIAP1. Collectively, these data 
indicate that, after induction of apoptosis, endogenous DIAP2 
and 1 are cleaved by caspases with similar kinetics.
DIAP2 cleavage is required to suppress 
drICE-mediated cell death
To determine the functional relevance of DIAP2 cleavage, we 
tested the ability of WT and noncleavable mutant DIAP2 to in-
hibit drICE-mediated cell death. Because ectopic expression of 
full-length drICE does not induce cell death in D. melanogaster 
tissue culture cells or transgenic fl  ies (Song et al., 2000), we 
used mammalian cells (NIH3T3) to study the ability of DIAP2 
to suppress drICE-mediated cell death. In this system, drICE 
expression is suffi  cient to trigger apoptosis (Fig. 4 A; Tenev et al., 
2005). Coexpression of DIAP1 and 2 provided protection against 
drICE-induced cell death. However, DIAP2
D100E, which lacks the 
caspase cleavage site, failed to provide signifi  cant protection 
(Fig. 4 B). Moreover, the BIR3 mutant DIAP2
C249G, which is 
impaired in drICE binding, also failed to inhibit this death. 
In contrast to drICE-induced cell death, DIAP2 was unable to 
suppress DCP-1–mediated apoptosis, whereas, under the same 
conditions, DIAP1 effi  ciently blocked DCP-1 killing (Fig. 4 C). 
This is in agreement with the notion that DIAP1 interacts with 
both drICE and DCP-1, whereas DIAP2 only associates with 
drICE (Leulier et al., 2006b).
Figure 3.  DIAP2 is cleaved at Asp100 by a z-VAD– and p35-sensitive caspase. (A) Schematic representation of DIAP2. The putative caspase cleavage site 
is underlined and boxed. Note, XIAP’s Asp148 (black circle) and Val146 (gray circle) are conserved in DIAP2 of D. melanogaster (D.mel), D. simulans 
(D.sim), D. yakuba (D.yak.), D. erecta (D.ere), and D. ananassae (D.ann) and in human cIAP1. DIAP1’s cleavage site is indicated as a dashed box. The 
  sequences were aligned according to ClustalX and anchored into the BIR2 of the indicated IAPs. (B) Endogenous DIAP2 is cleaved by an endogenous caspase. 
D. melanogaster S2 cells treated with the indicated conditions were lysed and DIAP2 was detected by immunoblotting with the indicated antibody. Actin 
was used as loading control. (C) In vitro cleavage assay using recombinant drICE and DIAP1 and 2. Asterisks indicate cross-reactive bands. (D) DIAP2 is 
cleaved at Asp100. DIAP2-GST and DIAP2
D100E-GST were expressed in S2 cells in the absence or presence of z-VAD-fmk. DIAP2 was puriﬁ  ed using GST-
beads and subjected to immunoblot analysis using anti-GST. (E) Endogenous DIAP2 is cleaved in response to UV treatment. Endogenous DIAP1, DIAP2, and 
drICE were detected by Western blot analysis using the indicated antibodies. Black lines indicate that the intervening lanes have been spliced out.JCB • VOLUME 179 • NUMBER 7 • 2007  1472
The DIAP2 cleavage site is required for 
drICE binding
Next, we investigated why DIAP2 cleavage is required for drICE 
inhibition. Crystal structure and mutational analysis   indicate 
that XIAP’s Val146 and Asp148 play a central role in the 
recognition of caspase-3 and -7, serving as anchoring residues 
for the hydrophobic and hydrophilic contact regions, respectively 
(Chai et al., 2001; Riedl et al., 2001a). Because the P1 residue of 
DIAP2’s caspase cleavage site (Asp100) corresponds to XIAP’s 
Asp148 (Fig. 3 A; Silke et al., 2001), we determined its involve-
ment in the binding to drICE. Although active drICE readily 
interacted with WT DIAP2 and DIAP2
78–498, its binding to the 
noncleavable DIAP2
D100E mutant was strongly   affected (Fig. 4 D). 
This suggests that Asp100 is required for the recognition of 
drICE, which provides a likely explanation for why DIAP2
D100E 
failed to block drICE-induced killing. However, the cleavage 
motif on its own was not suffi  cient to sustain DIAP2–drICE 
complex formation (Fig. S1 C). Thus, drICE binding occurs 
through a bimodular interaction that involves the BIR3 and 
Asp100. Our data indicate that BIR3 binding actually precedes 
binding to and cleavage of Asp100 (Fig. S2, available at http://
www.jcb.org/cgi/content/full/jcb.200706027/DC1).
We also tested whether the N-terminal region of DIAP2 needs 
to be cleaved for DIAP2 to bind to drICE. DIAP2
101–498, which lacks 
the N-terminal portion and hence mimics a cleaved form of DIAP2, 
failed to interact with drICE (Fig. 4 D, lane 5). Moreover, full-length 
WT DIAP2 readily bound to a fully processed drICE mutant 
(drICE
C211A; Fig. S3, available at available at http://www.jcb.org/
cgi/content/full/jcb.200706027/DC1). These observations indicate 
that the N-terminal portion of DIAP2 does not act as an autoinhibi-
tory region that might interfere with drICE binding.
Collectively, our observations are consistent with a model 
whereby DIAP2 binds to drICE through a mechanism that relies 
on the BIR3 domain and Asp100. Mutation of either motif ab-
rogates drICE binding. In contrast to XIAP, DIAP2 is effec-
tively cleaved at Asp100, which suggests that DIAP2 and XIAP 
bind to the caspases’ catalytic pocket differently.
DIAP2 functions as a mechanism-based 
regulator of drICE
DIAP2-mediated regulation of drICE strongly resembles the inhib-
itory mechanism of p35. p35 arrests caspase-mediated proteol-
ysis at the thioacyl intermediate stage, resulting in a   covalent 
p35–caspase complex in which the cleavage residue Asp87 of 
p35 links up with the catalytic cysteine of the caspase (Riedl 
et al., 2001b). We examined whether DIAP2 similarly traps the 
active caspase via a stable thio acyl linkage. To test this, we 
assessed the sensitivity of the DIAP2–drICE complex to treat-
ment with hydroxylamine (NH2OH), a strong nucleophile often 
used to break ester bonds that is known to abrogate p35-mediated 
caspase-3 inhibition (Riedl et al., 2001b). Thus, if the DIAP2–
drICE complex is indeed stabilized by a covalent thioacyl bond 
between Asp100 and the caspase’s catalytic cysteine, it should 
not form in the presence of NH2OH or DTT. Accordingly, DIAP2 
completely failed to bind to drICE in the presence of NH2OH 
(Fig. 5 A) or DTT (Fig. S4, available at http://www.jcb.org/cgi/
content/full/jcb.200706027/DC1). Under the same conditions, 
formation of the p35–drICE com  plex was weakened but not fully 
abrogated. In contrast, NH2OH did not affect the interaction 
of XIAP to caspase-3 (Fig. 5 B) nor did it abrogate DIAP1’s 
ability to bind drICE (not depicted). Importantly, NH2OH also 
did not disrupt DIAP2 binding in general because DIAP2 readily 
interacted with Rpr in the presence of NH2OH (Fig. 5 C). Further-
more, NH2OH and DTT did not interfere with the catalytic ac-
tivity of drICE because both DIAP2 and p35 were processed in 
the presence of NH2OH.
If DIAP2 traps the active caspase via a stable thioacyl 
linkage between Asp100 and the catalytic cysteine of the enzyme, 
Figure 4.  Asp100 of DIAP2 is required for drICE 
inhibition. (A–C) Expression of drICE and DCP-1 
leads to induction of apoptosis in NIH3T3 cells. 
(A) DIAP2 suppresses drICE-mediated cell death. 
(B) The cleavage site of DIAP2 was required to block 
drICE killing. (C) DIAP2 failed to inhibit DCP-1–
induced death. Shown are the percentages of 
β-galactosidase (β-Gal)–positive cells with apop-
totic morphology from three independent experi-
ments (mean ± SD). (D) Mutation of Asp100 to 
Glu-like deletion of the N-terminal 100 residues of 
DIAP2 abrogated drICE binding. The binding as-
say was performed as in Fig. 2.DIAP2-MEDIATED REGULATION OF DRICE • RIBEIRO ET AL. 1473
such linkage should not form with a processed catalytic mutant 
of drICE. Thus, the observed interaction between DIAP2 and 
processed drICE
C211A (Fig. S3) should be resistant to NH2OH 
because drICE
C211A lacks the catalytic thiol (Cys
211). Accord-
ingly, we found that NH2OH treatment did not interfere with the 
binding of DIAP2 to drICE
C211A, whereas it abrogated drICE
WT 
binding (Fig. 5 D). Note, the catalytic Cys is not involved in 
  positioning the scissile peptide bond across the catalytic appara-
tus. Residues of the substrate-binding pocket other than the 
catalytically active Cys mediate substrate binding (Timmer and 
Salvesen, 2007).
Collectively, our data are consistent with the notion that 
DIAP2 and WT drICE form a stable complex that critically 
depends on the P1 residue (Asp100) of DIAP2. Moreover, the 
stability of this complex is acutely sensitive to strong nucleo-
philes such as NH2OH or DTT, which is diagnostic of a sta-
ble thioester or disulfi  de adduct (Riedl et al., 2001b) between 
DIAP2 and drICE.
DIAP2 ubiquitylates drICE in a RING 
ﬁ  nger–dependent manner
To test the contribution of individual BIR and RING fi  nger do-
mains in regulating cell death in vivo, we examined their ability 
to block diap1 RNAi–mediated cell death. RNAi-mediated deple-
tion of DIAP1 triggers caspase-induced cell death, which is pre-
dominantly executed by drICE and occurs independently of the 
action of IAP antagonists (Leulier et al., 2006b). Expression of 
WT DIAP2 or DIAP2 mutants that carry single point mutations 
in either the BIR1 or 2 effi  ciently suppressed the eye phenotype 
caused by diap1 RNAi (Fig. 6; Leulier et al., 2006b). In con-
trast, a BIR3 mutant DIAP2 failed to rescue this phenotype, 
indicating that the BIR3 domain of DIAP2 is essential for apop-
tosis inhibition. This is consistent with our fi  nding that the BIR3, 
but not the BIR1 and 2, is indispensable for drICE binding. 
In addition, the RING fi  nger domain of DIAP2 was also required, 
as a DIAP2 RING mutant failed to suppress the diap1 RNAi 
phenotype (Fig. 6 F). This suggests that DIAP2 relies on its E3 
ubiquitin–protein ligase activity to block cell death. This notion 
is further supported by the observation that, in vitro, DIAP2 is 
unable to block drICE-mediated poly ADP ribose polymerase 
(PARP) cleavage (Fig. 6 G). Consistent with the involvement of 
the RING, we found that DIAP2 robustly ubiquitylates drICE in 
a RING fi  nger–dependent manner (Fig. 6 H). Moreover, a BIR3 
mutant (C249G) of DIAP2, which fails to bind drICE, also failed 
to ubiquitylate drICE (unpublished data). Collectively, these 
results suggest that DIAP2 blocks diap1 RNAi–mediated cell 
death by ubiquitylating drICE.
IAP antagonists display differential binding 
to speciﬁ  c BIR domains of DIAP2
The IAP antagonists Rpr, Grim, and Hid interact with DIAP1 
and 2 (Vucic et al., 1997; Vucic et al., 1998; Leulier et al., 2006b). 
When comparing the effi  ciency with which Rpr and Hid asso-
ciate with both these IAPs, we found that DIAP1 and 2 copuri-
fied comparable amounts of Rpr and Hid (Fig. 7 A; Leulier 
et al., 2006b), which suggests that Rpr and Hid target both 
IAPs equally. Rpr and Grim preferentially bound to the BIR2 
domain of DIAP2 because mutation of this domain abrogated 
DIAP2 association, whereas mutation of the BIR1 or 3 had no 
effect (Figs. 7 B and S5, available at http://www.jcb.org/cgi/
content/full/jcb.200706027/DC1). In contrast, Hid binding ap-
peared to be mediated by both BIR2 and 3 domains, as muta-
tion of both these domains was required to disrupt Hid binding 
(Fig. 7 C).
Hid blocks DIAP2 from binding to drICE
Because both Hid and drICE bind to the BIR3 domain of DIAP2, 
we tested whether Hid interfered with DIAP2’s ability to bind 
Figure 5.  DIAP2 and active drICE form a stable complex that is sensitive to nucleophile attack. (A) The interaction between DIAP2 and drICE is abrogated 
by exposure to 1 M NH2OH. (B) NH2OH exposure had no effect on the binding of XIAP with caspase-3, whereas it weakened the p35–caspase-3 inter-
action. (C) NH2OH did not affect the binding of Rpr to DIAP2 or 1. (D) DIAP2’s interaction with drICE
C211A is insensitive to NH2OH treatment. The binding 
  assay was performed as described in Fig. 2 except that NH2OH was added together with cell extracts containing either active drICE or caspase-3.JCB • VOLUME 179 • NUMBER 7 • 2007  1474
drICE. To this end, we coexpressed DIAP2-GST with AKG-
drICE
C211A in the presence or absence of Hid. AKG-drICE
C211A 
is a catalytic mutant of drICE that was expressed using the ubiq-
uitin fusion technique (Bachmair et al., 1986; Varshavsky, 2000; 
Tenev et al., 2005), which generates drICE with an unblocked 
N-terminal IBM through which it interacts with the BIR3 do-
main of DIAP2 (Fig. 2 B). drICE and Hid were both V5 tagged 
in this assay for direct comparison of protein expression levels. 
In the absence of Hid, DIAP2 readily copurifi  ed AKG-drICE 
(∆N-drICE) from cellular extracts (Fig. 7 D). When Hid was 
coexpressed, however, DIAP2 did not copurify drICE and in-
stead purifi  ed Hid, which demonstrates that Hid outcompetes 
drICE for free DIAP2. Of note, Hid was unable to displace 
drICE from a preformed DIAP2–drICE complex (unpublished 
data). Collectively these data indicate that Hid competes with 
drICE for DIAP2 binding rather than displacing it.
DIAP2 suppresses Hid killing independently 
of Hid binding
Overexpression of DIAP2 suppresses cell death induced by ec-
topic expression of IAP antagonists in the eye and cells in culture 
(Hay et al., 1995; Kaiser et al., 1998). Next we tested whether 
DIAP2 suppresses cell death by simply sequestering IAP antag-
onists away from DIAP1; or, alternatively, whether DIAP2 blocks 
apoptosis downstream of Hid. Induced expression of Hid trig-
gered apoptosis in 84% of D. melanogaster S2 cells within 24 h, 
whereas coexpression of DIAP2 or 1 effi  ciently suppressed Hid 
killing (Fig. 7 E). In contrast, the DIAP2 mutants DIAP2
D100E 
and DIAP2
101–498 were severely impaired in their ability to block 
Hid-induced cell death. Interestingly, these DIAP2 mutants 
bound to Hid as effi  ciently as WT DIAP2 (Fig. 7 F). Because 
both DIAP2 mutants were fully competent in Hid binding but 
greatly impaired in suppressing Hid killing, these data suggest 
that Hid binding is not suffi  cient to block Hid killing.
Discussion
Our data suggest that DIAP2 is a caspase regulator that contrib-
utes to the caspase activity threshold. Several lines of evidence 
support this view. First, loss of diap2 causes an increase in basal 
levels of caspase activity in vivo. Consistent with this increase 
in basal levels of caspase activity, diap2 mutant cells are sensi-
tized to sublethal doses of x-ray irradiation, and, in tissue culture 
cells, depletion of DIAP2 by RNAi sensitizes cells to treatment 
with chemotherapeutic drugs (Zimmermann et al., 2002). Second, 
DIAP2 overexpression in the developing fl  y eye effi  ciently sup-
presses cell death triggered by diap1 RNAi. Importantly, diap1 
RNAi causes spontaneous and unrestrained caspase activation 
and cell death (Wang et al., 1999; Goyal et al., 2000; Lisi et al., 
2000; Rodriguez et al., 2002) that occurs independently of the 
action of IAP antagonists (Leulier et al., 2006b). The effi  ciency 
with which DIAP2 rescues the diap1 RNAi phenotype is highly 
Figure 6.  The RING ﬁ  nger domain of DIAP2 is required for suppression of cell death induced by diap1 RNAi. The eye phenotype caused by DIAP1 deple-
tion (A) is rescued by expression of WT DIAP2 (B) and BIR1 (C) and BIR2 (D) mutants of DIAP2. Mutation in the BIR3 (E) or RING ﬁ  nger domain (F) failed 
to rescue this phenotype. Phenotypes were fully penetrant and representative ﬂ  y heads are shown. (G) Recombinant DIAP2 is unable to block drICE-mediated 
PARP cleavage in vitro, as assessed by immunoblot analysis using an anti-PARP antibody. (H) DIAP2 ubiquitylates drICE in a RING-dependent manner. 
His-ubiquitin and ∆N-drICE-V5 were coexpressed in S2-I cells with the indicated constructs. Ubiquitylated proteins were puriﬁ  ed and subject to Western blot 
analysis using the indicated antibodies. Genotypes used: w+;GMR-GAL4,UAS-diap1-IR/+ (A), w+;GMR-GAL4,UAS-diap1-IR/+;UAS-diap2
WT/+ (B), 
w+;GMR-GAL4,UAS-diap1-IR/UAS-diap2
C46G (BIR1
mut) (C), w+;GMR-GAL4,UAS-diap1-IR/UAS-diap2
C149G (BIR2
mut) (D), w+;GMR-GAL4,UAS-diap1-IR/+;
UAS-diap2
C249G (BIR3
mut)/+ (E), and w+;GMR-GAL4,UAS-diap1-IR/+;UAS-diap2
C466Y (RING
mut)/+ (F).DIAP2-MEDIATED REGULATION OF DRICE • RIBEIRO ET AL. 1475
reminiscent of that of p35. Both DIAP2 and p35 rescue the diap1 
RNAi eye size and pigmentation to an apparent normal morphol-
ogy but fail to restore the formation of bristles (Leulier et al., 
2006b). The notion that DIAP2 expression phenocopies the 
expression of p35, in the absence of any involvement of IAP 
antagonists, suggests that DIAP2 can function as a direct cas-
pase inhibitor for a p35-sensitive caspase. Third, DIAP2 physi-
cally interacts with the effector caspase drICE and suppresses 
drICE-mediated cell death. Fourth, endogenous DIAP2 is readily 
cleaved by caspases, which indicates that DIAP2 encounters 
Figure 7.  IAP antagonists thwart DIAP2 function. (A) DIAP2 and 1 bind to Rpr with comparable efﬁ  ciencies. (B) The BIR2 domain is required for Rpr binding. 
The indicated constructs were coexpressed in D. melanogaster S2/p35 cells. (C) Hid binds to the BIR2 and 3 of DIAP2. (D) In the presence of Hid, DIAP2 
failed to associate with drICE. DIAP2-GST was coexpressed with ∆N-drICE-V5 in D. melanogaster S2/p35 cells in the absence or presence of Hid-V5. 
(E and F) DIAP2-mediated inhibition of Hid-killing. (E) Hid-based killing assay in S2 cells in the presence or absence of DIAP1 and WT and mutant DIAP2. 
Shown are the percentages of viable, β-galactosidase–positive cells relative to controls from three independent experiments (mean ± SD). (F) Hid-binding 
study using mutant DIAP2.JCB • VOLUME 179 • NUMBER 7 • 2007  1476
caspases in vivo. Moreover, after induction of apoptosis, the 
timing and extent of DIAP2 cleavage is highly reminiscent to 
that of DIAP1, which suggests that cleavage of DIAP2 is a rela-
tively early event during apoptosis. Finally, IAP antagonists 
bind to DIAP1 and 2 with similar effi  ciencies. Consistent with 
the view that the caspase inhibitory activity of both IAPs is an-
tagonized by IAP antagonists, we fi  nd that Hid blocks DIAP1 
(Zachariou et al., 2003) and DIAP2 (this paper) from binding to 
drICE. Together, our data support a model in which DIAP1 and 2 
coordinately control drICE, thereby blocking the amplifi  cation 
of the caspase cascade (Fig. 8 A). Accordingly, DIAP2 con-
tributes to the apoptotic threshold by regulating drICE. However, 
DIAP1 controls initiation of apoptosis, as it is the sole IAP that 
regulates the initiator caspase Dronc and, with it, the formation 
of the Dronc/Dark apoptosome. Ultimately, programmed cell 
death is induced when IAP antagonists such as Hid synchro-
nously bind to DIAP1 and 2, allowing apoptosome formation and 
unhindered amplifi  cation of the caspase cascade.
Although DIAP2 seems to be a bona fi  de regulator of drICE, 
its loss does not cause spontaneous apoptosis. This is most likely 
caused by its epistatic position in the caspase cascade (Fig. 8 A) 
and its restricted specifi  city for caspases. Because DIAP2 ex-
clusively regulates drICE and does not bind other caspases 
(Leulier et al., 2006b; unpublished data), its loss merely causes 
an increase in caspase activity, presumably because of a small 
amount of uninhibited active drICE. Under such conditions, 
drICE activation remains regulated because it requires proteo-
lytic input from Dronc, which, in turn, is under the control of 
DIAP1. Although loss of DIAP2 results in sublethal levels of ac-
tive caspases, RNAi-mediated depletion of DIAP1 causes strong, 
apoptosome-driven activation of downstream effector caspases, 
which leads to the amplifi  cation of the proteolytic signal and 
death of the cell. Under diap1 RNAi conditions, levels of endog-
enous DIAP2 seem to be insuffi  cient to suppress the amount of 
active caspases generated. But, if the levels of DIAP2 are in-
creased, it effi  ciently blocks diap1 RNAi–mediated cell death. 
However, when programmed cell death is triggered through the 
activation of IAP antagonists, both IAPs are targeted equally, 
thereby releasing the inhibition of the cell death machinery. Thus, 
controlled activation of caspases and cell survival are ensured 
by both DIAP1 and 2.
The notion that diap2 mutant animals have increased lev-
els of caspase activity indicates that cells can generate and tolerate 
a certain amount of activated caspases without undergoing apop-
tosis. This is consistent with the notion that caspases fulfi  ll im-
portant signaling functions independent of executing cell death. 
For instance, DmIKKε activation was recently found to reduce 
DIAP1 protein levels, thereby allowing activation of sublethal 
levels of Dronc, which, in turn, is required for the proper develop-
ment of sensory organ precursor cells (Kuranaga et al., 2006). 
Thus, modulating caspase activity in a selective, transient, and 
possibly spatially restricted manner is likely to be a widespread 
phenomenon that allows caspases to take part in signaling func-
tions without jeopardizing cell viability. Concerted reduction of 
DIAP1 and 2 protein levels, or their controlled and selective in-
hibition, may therefore allow controlled activation of caspases 
and caspase-mediated signaling. The cellular concentration of 
IAPs would thereby set a cell type–specifi  c threshold for cas-
pase activation and activity. In DIAP2 mutants, however, cells 
are left in an unbalanced, sensitized state as they accumulate 
higher than normal levels of active caspases. Accordingly, diap2 
mutant third instar larvae are sensitized to apoptosis when sub-
jected to sublethal doses of x-ray irradiation. This sensitized state 
is only visualized by exposing diap2 mutant animals to sublethal 
insults. When strong proapoptotic stimuli are used, such as 40 Gy 
of x-ray irradiation (Huh et al., 2007) or overexpression of 
Rpr, Hid, and Grim, diap2 mutant animals display the same cell 
death phenotypes as WT counterparts (Huh et al., 2007; unpub-
lished data). Under these strong proapoptotic conditions, IAP 
antagonists neutralize both IAPs, causing full activation and 
amplifi  cation of the proteolytic caspase cascade. Thus, the con-
tribution of the sublethal amount of active caspases in diap2 
mutants seems to be masked by the higher concentration of active 
caspases generated under such apoptotic conditions.
Our molecular characterization has uncovered an un-
expected mechanism through which DIAP2 restrains the target 
enzyme drICE. Surprisingly, DIAP2 acts as a pseudosubstrate 
that, after cleavage, seems to trap the active caspase via a cova-
lent linkage between DIAP2 and the catalytic machinery of 
drICE. Mutation of the DIAP2 caspase cleavage site abrogates 
its ability to bind drICE and suppress drICE-mediated cell death. 
It is unusual for proteins that regulate enzymes to use a mechanism-
based strategy, and most types avoid the catalytic machinery by 
simply blocking the substrate cleft in a lock and key strategy. 
The cleavage of DIAP2 distinguishes it from all natural inhibitors 
with the exception of p35, CrmA, serpins, and α-macroglobulins. 
Serpins and p35 both require cleavage to function as protease 
inhibitors. p35 arrests proteolysis at the thioacyl intermediate 
stage, which results in a covalent adduct between p35 and the 
caspase. In particular, the cleavage site residue Asp87 of p35 
links up with the catalytic cysteine of the caspase (Riedl et al., 
2001b). Thus, cleaved p35 locks the catalytic machinery of the 
caspase in a nonproductive inactive confi  guration. The exquisite 
sensitivity of the DIAP2–drICE complex to strong nucleophiles 
such as NH2OH or DTT is diagnostic of a stable thioester 
adduct (Riedl et al., 2001b) between DIAP2 and drICE. Never-
theless, it remains possible that this complex could form be-
cause of a disulfi  de bridge between DIAP2 and the catalytic 
thiol of drICE. However, the requirement of DIAP2’s Asp100 
for drICE binding suggests that Asp100 is involved in forming 
a thioester covalent adduct with the caspase active site Cys. 
Ultimately, crystal structure or mass spectrometric analysis will 
be required to identify the chemical nature of this complex. 
However, the relatively harsh conditions required for sample prep-
arations for mass spectrometric analysis combined with the labile 
nature of thiol esters will make it diffi  cult to identify a fragment 
containing a covalent linkage between DIAP2 and drICE (Riedl 
et al., 2001b; Xu et al., 2001). Collectively, our data suggest that 
the DIAP2–drICE complex is stabilized by a covalent linkage 
(Fig. 8, B and C).
Despite the notion that p35 and DIAP2 both occupy and 
produce a covalent linkage with the active site of caspases, the 
modes of interaction and mechanism of inhibition are very differ-
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binding and inhibition. First, DIAP2 needs to associate with 
drICE through a bimodular interaction, whereby the BIR3 domain 
binds to the IBM of drICE and the 97-Ser-Val-Val-Asp-100 region 
of DIAP2 occupies the catalytic pocket of the caspase. Each 
motif on its own is insuffi  cient for caspase binding as mutation 
of either the BIR3 or cleavage site interferes with complex for-
mation. Second, physical interaction with drICE is not suffi  cient 
to block caspase activity. In addition, DIAP2 requires a functional 
RING fi  nger domain to regulate drICE-mediated cell death. 
This is evident because a DIAP2 RING fi  nger mutant fails to sup-
press cell death induced by RNAi-mediated depletion of DIAP1. 
Moreover, DIAP2 fails to suppress drICE in vitro. In this respect, 
DIAP2 functions as mechanism-based regulator (relying on the 
enzyme’s catalytic property to trap it) rather than inhibitor. After 
capture, DIAP2 targets drICE for ubiquitylation (Fig. 8).
An important question is why DIAP2 does not function as 
an inhibitor like p35 if it also establishes a covalent linkage with 
the catalytic active site cysteine of the caspase. One possibility 
is that DIAP2 and p35 differ in their ability to protect the highly 
labile thioester bond from hydrolysis. This view is supported 
by the notion that the DIAP2–drICE interaction is signifi  cantly 
more sensitive to nucleophile attack than p35–drICE. Thus, in 
the situation of DIAP2, the thioester linkage with drICE may 
simply help to stabilize the caspase interaction, whereas in p35–
drICE, it is used to irreversibly inhibit the protease. The more 
labile nature of the DIAP2–drICE complex may allow regulation, 
which cannot occur with p35. Moreover, p35 inhibits all effec-
tor caspases, whereas DIAP2 only regulates drICE. The obser-
vation that the nontarget caspase DCP-1 can also cleave DIAP2 
but is not inhibited raises the possibility that DCP-1 controls the 
level of functional DIAP2 through proteolytic inactivation. 
  Examples of such regulation are manifold and include the proteo-
lytic inactivation of serpins by nontarget proteases (Gettins, 2002). 
Because DIAP2 tightly interacts with drICE, it is likely to control 
its apoptotic and nonapoptotic functions.
Materials and methods
Generation of constructs and antibodies
DIAP2 constructs were cloned into pcDNA3 and C-terminally tagged with 
TAP (provided by B. Seraphin, Centre National de la Recherche Scientiﬁ  que, 
Gif-sur-Yvette, France; Rigaut et al., 1999). Point mutants were generated 
by site-directed mutagenesis (Stratagene) according to the manufacturer’s 
Figure 8.  IAP-mediated regulation of caspases. (A) Schematic representation of the caspase cascade in D. melanogaster depicting DIAP2’s epistatic posi-
tion. Arrows denote activation and bars represent suppression. Bold arrows denote the predominant role of drICE downstream of apoptosome activation. 
(B and C) Comparison of DIAP2- and DIAP1-mediated regulation of effector caspases. JCB • VOLUME 179 • NUMBER 7 • 2007  1478
instructions. WT (SVVDS) and mutant (SVVES) DIAP2 cleavage site motifs 
were N-terminally fused to TAP. For ubiquitylation assays, untagged DIAP2, 
DIAP2
C466Y, or DIAP2
C249G were cloned in pAcV5/His. For recombinant 
assays, DIAP1 and 2 were cloned into pGEX-6P-1 and N-terminally tagged 
with GST and C-terminally tagged with V5 His, whereas drICE was cloned 
into pGEX-5X-3 and C-terminally tagged with V5 His. drICE-V5, drICE
A29V-
V5,  ∆N–drICE
29-339/C211A-V5, Rpr-V5, Grim-V5, Hid-V5, DEP1-TAP, and 
anti-drICE and anti-BIR3 DIAP2 antibodies were described previously 
(Tenev et al., 2005; Leulier et al., 2006b). Constructs were generated by 
PCR and veriﬁ  ed by DNA sequencing. Anti-V5 (AbD Serotec), anti-GST 
(GE Healthcare), anti-actin (Santa Cruz Biotechnology, Inc.), and biotin-
calmodulin (EMD) were used according to the manufacturers’ instructions.
Tissue culture and cell death assays
S2, S2-I, HEK293T, and NIH3T3 cells were cultured as described previ-
ously (Tenev et al., 2005) and transfected with either calcium phosphate 
(BD Biosciences), Effectene (QIAGEN), or Cellfectin (Invitrogen). Apoptosis 
assays were performed as described previously (Tenev et al., 2002). 
In brief, 0.09 × 10
6 NIH3T3 cells were transfected with the following DNA 
ratios: drICE, 26%; DIAP1/DIAP2, 54%; and LacZ, 20%; 1 μg total. Cells 
were assayed for β-galactosidase (β-Gal) activity after 24 h and cell viability 
was determined based on morphology of at least 900 β-Gal–positive cells. 
Live blue cells were scored and expressed as a percentage of total positively 
transfected blue cells, which was established by treating cells with z-VAD-fmk 
(BIOMOL International, L.P.). Note, z-VAD-fmk treatment allows normalization 
of differences in transfection efﬁ  ciencies. In Fig. 7 (E and F), S2 and S2/p35 
cells stably expressing p35 were used. In brief, S2 cells were seeded into 
a 24-well plate and transfected with the following DNA ratios: Hid, 58%; 
DIAP1/DIAP2, 40%; and LacZ, 2%; 0.5 μg total. 24 h after transfection, 
cells were assayed for β-Gal activity.
Ubiquitylation assay
S2 cells with constitutively knocked-down endogenous DIAP2 (S2-I cells) 
were used. S2-I cells were derived from S2 cells by constitutively express-
ing diap2-IR, which consists of diap2’s 3′ untranslated region sequence 
separated by the intronic sequence of the Ret gene (Pili-Floury et al., 2004). 
S2-I cells were cotransfected with His-ubiquitin and ∆N-drICE-V5 together 
with either vector control, WT DIAP2, DIAP2
C466Y, or DIAP2
C249G. The follow-
ing DNA ratios were used: ubiquitin, 60%; drICE, 20%; and DIAP2, 20%; 
2.5 μg total. Cells were harvested and washed once in PBS. 10% of the 
cells were lysed in 50 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100, 
10% glycerol, and 1 mM EDTA lysis buffer and extracts, whereas the rest was 
lysed in guanidinium lysis buffer I (6 M guanidinium-HCl, 100 mM NaH2PO4, 
10 mM Tris-HCl, pH 8, 5 mM imidazole, and 10 mM β-mercaptoethanol). 
Ubiquitylated proteins were puriﬁ  ed using Ni-NTA agarose beads (QIAGEN) 
as described previously (Rodriguez et al., 1999) and eluted using 200 mM 
imidazole, 150 mM Tris, pH 6.8, 30% glycerol, 720 mM β-mercaptoethanol, 
and 5% SDS.
Chemicals and UV treatment
S2 cells were UV irradiated at 150 kμJ and lysed at the indicated time 
points. z-VAD-fmk was used at a ﬁ  nal concentration of 40 μM. In recombi-
nant assays, a ﬁ  nal concentration of 50 μM was used. 1M NH2OH and 
16 mM DTT (Sigma-Aldrich) was added to DIAP2 together with drICE-
expressing lysate.
Cleavage assay
TAP-puriﬁ  ed DIAP2 was incubated with lysates of 293T cells expressing 
drICE or drICE
A29V. The in vitro cleavage reaction was performed in 10 mM 
Tris, pH 7.5, 150 mM NaCl, 2 mM DTT, and 0.1% Triton X-100 at room 
temperature for the indicated time points.
Immunoprecipitation and immunoblot analysis
Immunoprecipitation assays were performed as described previously 
(Tenev et al., 2005). In brief, cells were lysed in 50 mM Tris, pH 7.5, 150 mM 
NaCl, 1% Triton X-100, 10% glycerol, and 1 mM EDTA and extracts 
were spun at 14,000 rpm for 10 min at 4°C. GST- or TAP-tagged proteins 
were puriﬁ  ed using glutathione- or IgG-coupled Sepharose 4B beads (GE 
Healthcare), respectively. After 1-h incubation, beads were washed three 
times in 10 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Triton X-100, and 5% 
glycerol. To assess DIAP2 binding, puriﬁ  ed and immobilized DIAP2 was 
exposed to extracts from 293T cells expressing drICE. Processed active-site 
mutant drICE
C211A was generated by incubating drICE
C211A-expressing cells 
with 50 μM MG132 (Sigma-Aldrich). DIAP2-bound samples were washed 
and examined by immunoblot analysis using either chemiluminescence 
(GE Healthcare) or Odyssey technology (LI-COR Biosciences). GST alone 
or GST-tagged DIAP1 or 2 were coexpressed with RprV5 in D. melanogaster 
S2/p35 cells.
In vitro assays
Recombinant active drICE was puriﬁ  ed from bacterial lysates using Ni-NTA 
agarose beads (QIAGEN) according to the manufacturer’s instructions. 
  Recombinant DIAP1 and 2 were obtained by sequential use of Ni-NTA aga-
rose (His puriﬁ  cation) and glutathione-Sepharose beads (GST puriﬁ  cation). 
For drICE-mediated PARP cleavage, reactions were performed with 4 μg of 
recombinant PARP (R&D Systems), 0.5 μg of DIAP1, DIAP2, or GST, and 
160 ng of in vitro puriﬁ  ed active drICE. PARP cleavage reactions were per-
formed at room temperature in 100 μl of in vitro cleavage buffer (10 mM 
Tris, pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 5% glycerol, and 1 mM 
DTT). Note that drICE was incubated for 30 min with IAPs before the addi-
tion of PARP for 30 min. For drICE-mediated cleavage of IAPs, 25 ng of in 
vitro puriﬁ  ed active drICE were incubated with 0.25 μg of recombinant 
GST, DIAP1, or DIAP2. Reactions were performed in 50 μl of in vitro cleav-
age buffer for 1 h at room temperature. In both assays, z-VAD-fmk was 
used in a ﬁ  nal concentration of 50 μM.
Fly strains, crosses, and x-ray irradiation
diap2 mutant ﬂ  ies were described previously (Leulier et al., 2006a). Crosses 
were performed at 25°C. Third instar larvae were x-ray irradiated with 1.5 Gy. 
After 4 h of recovery, wing imaginal discs were isolated and stained with 
AO (Abrams et al., 1993). Quantiﬁ  cation of AO-stained cells was performed 
with Photoshop CS2 (Adobe) with a threshold setting of 100 (scoring only 
strongly stained cells). Untagged DIAP2, DIAP2
C46G, DIAP2
C149G, DIAP2
C249G, 
and DIAP2
C466Y were cloned into pUAST and transgenic ﬂ  ies were generated 
(Leulier et al., 2006a). The diap2 rescue construct was generated by cloning 
a WT genomic fragment of 3.3 kb covering the diap2 locus in pCasper4.
Image acquisition
Images of adult heads were acquired using a stereo microscope (MZ APO; 
Leica) equipped with a Plan Apo 1.0× lens using a digital camera (D1; 
Nikon) and software (Capture; Nikon). Images of AO-stained wing discs 
were taken using an Axiovert 100 (Carl Zeiss, Inc.) with a 20×/0.3 lens 
using the aforementioned mentioned digital camera and software. Quanti-
ﬁ  cation of AO-positive cells was done using Photoshop CS2 software by 
applying a threshold ﬁ  lter of 100 to all images collected, allowing the scor-
ing of only strongly stained cells. All images were taken at room tempera-
ture and processed with Photoshop CS2 software. Images were linearly 
rescaled to optimize brightness and contrast uniformly without altering, 
masking, or eliminating data. Confocal FRET images were acquired on 
the Aquacosmos/Ashura system (Hamamatsu Photonics) using an IX-71 
equipped with a UPlan Apo10×/040 NA objective (Olympus), a spinning 
disk-type confocal unit (CSU10; Yokogawa), a diode-pumped solid-state 
laser (430 nm; Melles Griot), and a three charge-coupled device color 
camera (C7780-22; Hamamatsu Photonics). Image acquisition and analysis 
were performed using Aquacosmos/Ashura software.
FRET assay
The confocal imaging analysis of FRET-based caspase activation was per-
formed as described previously (Takemoto et al., 2003). FRET ratio data 
were collected from >10 ﬂ  ies. After the acquisition of each image (inten-
sity of CFP-CFP and CFP-Venus), the background signal was subtracted. 
The ratio image (Venus intensity/CFP intensity) was made for each individ-
ual tissue and the average ratio was calculated in all pixels of the area in 
which SCAT3 was expressed.
Online supplemental material
Fig. S1 shows additional experiments for DIAP2–drICE interaction. Fig. S2 
shows kinetics studies of DIAP2 cleavage. Fig. S3 shows interaction of 
DIAP2 with drICE
C211A. Fig. S4 shows the inﬂ  uence of DTT in DIAP2–drICE 
binding. Fig. S5 shows the interactions of DIAP2 with Rpr and Grim. 
Online supplemental material is available at http://www.jcb.org/cgi/
content/full/jcb.200706027/DC1.
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